Company profile
Armata Pharmaceuticals, Inc.
AMEX:ARMPBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| C16G2 | phase2 | — | 5 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03196219 | phase2 | completed | 2017-07-07 | 2017-11-22 | Armata Pharmaceuticals, Inc. | A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects |
| NCT03052842 | phase2 | completed | 2017-02-09 | 2017-04-05 | Armata Pharmaceuticals, Inc. | A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application |
| NCT03004365 | phase2 | completed | 2017-01-27 | 2017-03-29 | Armata Pharmaceuticals, Inc. | A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects |
| NCT02757755 | phase1 | completed | 2016-05-01 | 2016-08-01 | Armata Pharmaceuticals, Inc. | Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults |
| NCT04596319 | phase1_2 | completed | 2020-12-22 | 2022-12-14 | Armata Pharmaceuticals, Inc. | Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis |
FDA applications (0)
No records yet.